Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics

• See Rakovina Therapeutic’s journey of pivoting a DDR-focused biotech to a fully AI-driven discovery model

• Illustrating case studies of AI-designed DDR programs advancing through preclinical lead selection

• Evaluating predictive accuracy, translational potential, and long-term impact of AI on drug development

Speakers:

Mads Daugaard

Co-founder, President & Chief Scientific Officer

Rakovina Therapeutics, Inc.